In April 1999, Astra AB and Zeneca Group PLC merged to form AstraZeneca, one of the world's leading pharmaceutical and agrochemical companies, which provides innovative, effective products to improve health, nutrition and quality of life worldwide. The company is research and technology intensive, with extensive international development and marketing skills. Its healthcare business is strategically focused on seven major therapeutic areas: gastrointestinal, oncology, pain control and anaesthesia, cardiovascular, central nervous system, respiratory and infection. Zeneca Agrochemicals provides crop protection products designed to improve crop yields and food quality.
Printable copy
Alternatively you can print out each section on its own by clicking "Go to Printable Version" at the top of each page. The page will open in a new browser window without the left-hand menu. Before printing, ensure you have your background printing option turned on.IE4 users should go to their browser menu and select the following: View, Internet Options, Advanced. Then scroll down to Printing and ensure the check box marked Print background colours and images is selected.
US users
Swedish users
Download a printable copy of the Annual Report and Form 20-F with Adobe Acrobat:
Download Part 1
Download Part 2
You will need the Adobe Acrobat Reader which can be downloaded free from the Adobe site.
Click here for the US AstraZeneca Annual Report and Cross Reference to Form 20-F.
Click here for the Swedish version of the AstraZeneca Annual Report and Form 20-F.
In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Annual Report and Form 20-F 1999 contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability and the risks related to the difficulty of integrating Astra's and Zeneca's large and complex businesses on a timely basis and realising synergies.
© AstraZeneca PLC 2000
This site has been optimised for Internet Explorer 4
